Full Press Release Details
("Midatech" or the "Company")
Result of 2021 Annual General Meeting
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that at its
Annual General Meeting (AGM) held at 11.30am today all resolutions put to the meeting were duly passed.
For more information,
| Midatech Pharma PLC |
| Stephen Stamp, CEO, CFO |
| Tel: +44 (0)29 2048 0180 |
| www.midatechpharma.com |
| Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) |
| Freddy Crossley, Emma Earl (Corporate Finance) |
| Rupert Dearden (Corporate Broking) |
| Tel: +44 (0)20 7886 2500 |
| Turner Pope Investments (TPI) Limited (Joint Broker, Sole Bookrunner) |
| Andrew Thacker / James Pope (Corporate Broking) Tel: +44(0)20 3657 0050 |
| IFC Advisory Limited (Financial PR and UK Investor Relations) |
| Tim Metcalfe / Graham Herring |
| Tel: +44 (0)20 3934 6630 |
| Email: midatech@investor-focus.co.uk |
| Edison Group (US Investor Relations) Maxwell Colbert Tel: +1 (646) 653 7028 mcolbert@edisongroup.com |
About Midatech Pharma
Midatech Pharma PLC (dual listed on LSE AIM: MTPH;
and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The
Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling
products that have the potential to powerfully impact the lives of patients.
The Company has developed three in-house technology
platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies
have successfully entered human use in the clinic, providing important validation of the potential for each platform:
The platform nature of the technologies offers
the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies
are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and
R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com